Sleepwalking [somnambulism]
Methodology & AI Transparency ⓘ
Sleepwalking [somnambulism] Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Within Insomnia, Sleep Apnea & Sleep Health practice, Sleepwalking [somnambulism] (ICD-10 F51.3) is stratified through home sleep apnea in Sleepwalking [somnambulism] (F51.3: testing (HSAT) or), pairing targeted symptom control with longitudinal Insomnia Severity Index in Sleepwalking [somnambulism] (F51.3: (ISI)) surveillance.
- 2 Real-world patient consensus: Federal ICD-10-CM code F51.3 categorizes Sleepwalking [somnambulism] under Insomnia, Sleep Apnea & Sleep Health.
- 3 Typical cash cost range: Clinicians assessing Sleepwalking [somnambulism] focus on suprachiasmatic nucleus circadian in Sleepwalking [somnambulism] (F51.3: phase misalignment) and targeted history.
- 4 Top reported side effects / signs: Key Sleep Disorders biomarkers for Sleepwalking [somnambulism] (F51.3): Apnea-Hypopnea Index (AHI) [Sleepwalking [somnambulism] F51.3] & Insomnia Severity Index in Sleepwalking [somnambulism] (F51.3: (ISI)) (< 7 (F51.3)).
Ask our AI Specialists anything about Sleepwalking [somnambulism]
What Is Sleepwalking [somnambulism]?
Within Insomnia, Sleep Apnea & Sleep Health practice, Sleepwalking [somnambulism] (ICD-10 F51.3) is stratified through home sleep apnea in Sleepwalking [somnambulism] (F51.3: testing (HSAT) or), pairing targeted symptom control with longitudinal Insomnia Severity Index in Sleepwalking [somnambulism] (F51.3: (ISI)) surveillance.
Pathophysiology, Underlying Causes & Clinical Presentation
Sleepwalking [somnambulism] (F51.3) alters sleep disorders homeostasis through suprachiasmatic nucleus circadian in Sleepwalking [somnambulism] (F51.3: phase misalignment); clinical remission targets Insomnia Severity Index in Sleepwalking [somnambulism] (F51.3: (ISI)) within < 7 (F51.3).
Common Symptoms & Clinical Signs
- • Presentation of Sleepwalking [somnambulism] (F51.3): prolonged sleep-onset latency [Sleepwalking [somnambulism] F51.3]
- • Secondary Sleepwalking [somnambulism] clinical sign: unrefreshing morning waking in Sleepwalking [somnambulism] (F51.3: despite adequate hours)
- • Symptom flares in Sleepwalking [somnambulism] correlating with Apnea-Hypopnea Index (AHI) [Sleepwalking [somnambulism] F51.3] deviation outside < 5 events/hour (F51.3)
- • Functional sleep disorders impact requiring home sleep apnea in Sleepwalking [somnambulism] (F51.3: testing (HSAT) or) evaluation (F51.3)
Sleepwalking [somnambulism] Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F51.3 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Insomnia, Sleep Apnea & Sleep Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Apnea-Hypopnea Index (AHI) [Sleepwalking [somnambulism] F51.3] | < 5 events/hour (F51.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Insomnia Severity Index in Sleepwalking [somnambulism] (F51.3: (ISI)) | < 7 (F51.3) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Nocturnal Oxygen Saturation in Sleepwalking [somnambulism] (F51.3: (SpO2)) | >= 94% nadir > 90% (F51.3) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Sleepwalking [somnambulism]
Treatment selection for Sleepwalking [somnambulism] depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Sleepwalking [somnambulism])
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Association of epicardial adipose tissues with obstructive sleep apnea and its: What a 1,178-Participant Study Found EAT thickness was shown to be higher in patients with OSA than in patients with non-OSA measured by echocardiography. Nutrition, metabolism, and cardiovascular diseases : NMCD • 2020-06-25 • Meta-Analysis | N = 1,178 | 94/100 | PMID 32446869 ↗ |
| New Insights on Remibrutinib impact on disease control, sleep, and quality of life: Analysis of: What a 306-Participant Study Found Remibrutinib exhibited fast improvements in disease control, sleep, and QoL in REMIX-1 and REMIX-2, supporting remibrutinib as a valuable therapeutic option for CSU. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology • 2026-09-15 • Phase III Randomized Trial | N = 306 | 93/100 | PMID 42297099 ↗ |
| Can This Approach Help? Inside the Latest Research on Melatonin decreases daytime challenging behaviour in persons with intellectual Melatonin treatment in persons with ID and chronic trouble sleeping decreases daytime challenging behaviour, probably by improving sleep maintenance or by improving circadian melatonin rhythmicity. Journal of intellectual disability research : JIDR • 2010-01-01 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 19888921 ↗ |
| Can This Approach Help? Inside the Latest Research on Melatonin for chronic sleep onset trouble sleeping in children: a randomized The results show that melatonin, 5 mg at 6 PM, was relatively safe to take in the short term and significantly more effective than placebo in advancing sleep onset and dim light melatonin onset and increasing sleep duration in... Journal of child neurology • 2001-02-15 • Randomized Controlled Trial | N = 33 | 88/100 | PMID 11292231 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of lemborexant on sleep architecture in participants with trouble sleeping LEM significantly increased TST in participants with trouble sleeping and mild OSA. Sleep medicine • 2025-03-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 39879708 ↗ |
Sleepwalking [somnambulism] Patient Community & “People Like Me” Threads
Filter Sleepwalking [somnambulism] community threads and patient logs by age, biological sex, dosage, and treatment duration.